Cargando…

Transient postprandial increase in intact circulating fibroblast growth factor-21 levels after Roux-en-Y gastric bypass: a randomized controlled clinical trial

BACKGROUND: Despite a consistent link between obesity and increased circulating levels of fibroblast growth factor-21 (FGF21), the effect of weight-loss interventions on FGF21 is not clear. We aimed to determine the short- and long-term effects of Roux-en-Y gastric bypass (RYGB) on intact plasma FGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Nielsen, Mette S., Søberg, Susanna, Schmidt, Julie B., Chenchar, Anne, Sjödin, Anders, Gillum, Matthew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052976/
https://www.ncbi.nlm.nih.gov/pubmed/33954037
http://dx.doi.org/10.7717/peerj.11174
_version_ 1783680030100946944
author Nielsen, Mette S.
Søberg, Susanna
Schmidt, Julie B.
Chenchar, Anne
Sjödin, Anders
Gillum, Matthew P.
author_facet Nielsen, Mette S.
Søberg, Susanna
Schmidt, Julie B.
Chenchar, Anne
Sjödin, Anders
Gillum, Matthew P.
author_sort Nielsen, Mette S.
collection PubMed
description BACKGROUND: Despite a consistent link between obesity and increased circulating levels of fibroblast growth factor-21 (FGF21), the effect of weight-loss interventions on FGF21 is not clear. We aimed to determine the short- and long-term effects of Roux-en-Y gastric bypass (RYGB) on intact plasma FGF21 levels and to test the hypothesis that RYGB, but not diet-induced weight loss, increases fasting and postprandial responses of FGF21. METHOD: Twenty-eight participants with obesity followed a low-calorie diet for 11 weeks. The 28 participants were randomized to undergo RYGB surgery at week 8 (RYGB group, n = 14), or to a control group scheduled for surgery at week 12 (n = 14). Fasting levels of intact, biologically active FGF21 (amino acids 1-181) and its postprandial responses to a mixed meal were assessed at week 7 and 11, and 78 weeks (18 months) after RYGB. RESULTS: At week 11 (3 weeks after RYGB), postprandial responses of intact FGF21 were enhanced in participants undergoing surgery at week 8 (change from week 7 to 11: P = 0.02), whereas no change was found in non-operated control participants in similar negative energy balance (change from week 7 to 11: P = 0.81). However, no between-group difference was found (P = 0.27 for the group-week-time interaction). Fasting, as well as postprandial responses in intact FGF21, were unchanged 18 months after RYGB when both the RYGB and control group were collapsed together (change from week 7 to 78 weeks after RYGB: P = 0.17). CONCLUSION: Postprandial intact FGF21 levels were enhanced acutely after RYGB whereas no signs of sustained changes were found 18 months after surgery. When comparing the acute effect of RYGB with controls in similar negative energy balance, we failed to detect any significant differences between groups, probably due to the small sample size and large inter-individual variations, especially in response to surgery.
format Online
Article
Text
id pubmed-8052976
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-80529762021-05-04 Transient postprandial increase in intact circulating fibroblast growth factor-21 levels after Roux-en-Y gastric bypass: a randomized controlled clinical trial Nielsen, Mette S. Søberg, Susanna Schmidt, Julie B. Chenchar, Anne Sjödin, Anders Gillum, Matthew P. PeerJ Clinical Trials BACKGROUND: Despite a consistent link between obesity and increased circulating levels of fibroblast growth factor-21 (FGF21), the effect of weight-loss interventions on FGF21 is not clear. We aimed to determine the short- and long-term effects of Roux-en-Y gastric bypass (RYGB) on intact plasma FGF21 levels and to test the hypothesis that RYGB, but not diet-induced weight loss, increases fasting and postprandial responses of FGF21. METHOD: Twenty-eight participants with obesity followed a low-calorie diet for 11 weeks. The 28 participants were randomized to undergo RYGB surgery at week 8 (RYGB group, n = 14), or to a control group scheduled for surgery at week 12 (n = 14). Fasting levels of intact, biologically active FGF21 (amino acids 1-181) and its postprandial responses to a mixed meal were assessed at week 7 and 11, and 78 weeks (18 months) after RYGB. RESULTS: At week 11 (3 weeks after RYGB), postprandial responses of intact FGF21 were enhanced in participants undergoing surgery at week 8 (change from week 7 to 11: P = 0.02), whereas no change was found in non-operated control participants in similar negative energy balance (change from week 7 to 11: P = 0.81). However, no between-group difference was found (P = 0.27 for the group-week-time interaction). Fasting, as well as postprandial responses in intact FGF21, were unchanged 18 months after RYGB when both the RYGB and control group were collapsed together (change from week 7 to 78 weeks after RYGB: P = 0.17). CONCLUSION: Postprandial intact FGF21 levels were enhanced acutely after RYGB whereas no signs of sustained changes were found 18 months after surgery. When comparing the acute effect of RYGB with controls in similar negative energy balance, we failed to detect any significant differences between groups, probably due to the small sample size and large inter-individual variations, especially in response to surgery. PeerJ Inc. 2021-04-14 /pmc/articles/PMC8052976/ /pubmed/33954037 http://dx.doi.org/10.7717/peerj.11174 Text en © 2021 Nielsen et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Clinical Trials
Nielsen, Mette S.
Søberg, Susanna
Schmidt, Julie B.
Chenchar, Anne
Sjödin, Anders
Gillum, Matthew P.
Transient postprandial increase in intact circulating fibroblast growth factor-21 levels after Roux-en-Y gastric bypass: a randomized controlled clinical trial
title Transient postprandial increase in intact circulating fibroblast growth factor-21 levels after Roux-en-Y gastric bypass: a randomized controlled clinical trial
title_full Transient postprandial increase in intact circulating fibroblast growth factor-21 levels after Roux-en-Y gastric bypass: a randomized controlled clinical trial
title_fullStr Transient postprandial increase in intact circulating fibroblast growth factor-21 levels after Roux-en-Y gastric bypass: a randomized controlled clinical trial
title_full_unstemmed Transient postprandial increase in intact circulating fibroblast growth factor-21 levels after Roux-en-Y gastric bypass: a randomized controlled clinical trial
title_short Transient postprandial increase in intact circulating fibroblast growth factor-21 levels after Roux-en-Y gastric bypass: a randomized controlled clinical trial
title_sort transient postprandial increase in intact circulating fibroblast growth factor-21 levels after roux-en-y gastric bypass: a randomized controlled clinical trial
topic Clinical Trials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052976/
https://www.ncbi.nlm.nih.gov/pubmed/33954037
http://dx.doi.org/10.7717/peerj.11174
work_keys_str_mv AT nielsenmettes transientpostprandialincreaseinintactcirculatingfibroblastgrowthfactor21levelsafterrouxenygastricbypassarandomizedcontrolledclinicaltrial
AT søbergsusanna transientpostprandialincreaseinintactcirculatingfibroblastgrowthfactor21levelsafterrouxenygastricbypassarandomizedcontrolledclinicaltrial
AT schmidtjulieb transientpostprandialincreaseinintactcirculatingfibroblastgrowthfactor21levelsafterrouxenygastricbypassarandomizedcontrolledclinicaltrial
AT chencharanne transientpostprandialincreaseinintactcirculatingfibroblastgrowthfactor21levelsafterrouxenygastricbypassarandomizedcontrolledclinicaltrial
AT sjodinanders transientpostprandialincreaseinintactcirculatingfibroblastgrowthfactor21levelsafterrouxenygastricbypassarandomizedcontrolledclinicaltrial
AT gillummatthewp transientpostprandialincreaseinintactcirculatingfibroblastgrowthfactor21levelsafterrouxenygastricbypassarandomizedcontrolledclinicaltrial